HBsAg concentrations and aspartate transaminase. No such changes occurred in the control groups.
Although ARA-A has a low toxicity, relative to other antiviral agents,8 its usefulness is limited by insolubility and the need for continuous intravenous administration. Adenine arabinoside 5'-monophosphate (ARA-AMP), the synthetic monophosphate ester of ARA-A, is at least 400 times more water soluble. It is therefore suitable for intramuscular or intravenous administration. The aim of this study was to determine whether ARA-AMP would also inhibit HBV replication and, if so, to determine an effective and convenient dosage regime.
Methods

PATIENTS
Initially five HBsAg positive males, age range 29-56 years, were treated with ARA-AMP 10 or 15 mg/kg/day intravenously or intramuscularly for nine to 14 days. All were serum HBeAg and HBV-DNA polymerase positive. Each had chronic active liver disease proven by biopsy and had been chronically infected and untreated for one to four years. In particular they had never received immuno-suppressant therapy (Table 1) . Case 1, an intravenous drug abuser, defaulted on the ninth day of treatment. Case 4 had a second course of treatment at higher dosage two months after the first. Case 5 was given a lower dosage (5 mg/kg) bf ARA-AMP at the end of the initial treatment period to assess the effectiveness of the reduced dose in maintaining inhibition of HBV-DNA polymerase activity.
Subsequently and consecutively three HBsAg/ HBeAg/HBV-DNA polymerase positive males, age range 28-36 years, with histologically proven chronic active liver disease for one to three years, who also had not received antiviral or immunosuppressant therapy, were treated with ARA-AMP at the lower dose of 5 mg/kg/day given 12 hourly intramuscularly. In two cases it was given for 16 and 19 days after five days of ARA-AMP at 10 mg/kg! day and, in one case, the low dose was given throughout for 34 days. Two cases were treated as outpatients. On microscopy there were no red cell casts and the haematuria disappeared spontaneously while treatment continued. Intravenous pyelography and cystoscopy were normal. All patients complained of lethargy during treatment. Two patients experi-enced transient nausea during the first two days of treatment. One patient had diarrhoea for two days after the treatment stopped.
CASES 6-8 (Long course ARA-AMP) All three cases showed inhibition of DNA polymerase activity (Fig. 2) . In cases 6 and 7 there was a rebound on stopping therapy but then a fall into the negative range. In each case inhibition of DNA polymerase activity was prolonged and associated with a fall in HBeAg titre. In three to seven months after treatment HBeAg became undetectable, with the development of anti-HBe and a decrease in HBsAg concentration in all three cases. Serum viral DNA in cases 7 and 8 became undetectable during treatment (Fig. 3) . In case 7 low amounts were detectable at the time of appearance of anti-HBe. There was a 73 to 96% reduction during treatment in case 6 with a rebound but then viral DNA became undetectable with the appearance of anti-HBe. The patients have remained anti-HBe positive for eight to 13 months after treatment. There was a marked rise in AST after therapy but in each case this has returned to below pre-treatment levels ( The rebound in DNA polymerase activity after therapy and delay in loss of HBeAg suggests that the direct antiviral activity of ARA-AMP may only be part of the mechanism involved in producing prolonged inhibition of viral replication. The associated rise in AST after treatment in those that later seroconverted suggests that hepatocyte lysis is also involved in the process. This raises the possibility that enhancement of the immune response to the virus or virally determined antigens, perhaps facilitated by a preceding lowering of viral load, is an important component.
The aim of antiviral therapy in patients with chronic HBV infection is to reduce infectivity and to reduce hepatic inflammatory activity. As it is well established that blood from anti-HBe positive patients is relatively less infectious than blood from HBeAg positive individuals,14 it is highly probable that our patients who have developed anti-HBe after therapy have undergone a substantial reduction in infectivity. This contention is further supported by the disappearance from the serum of the HBV-DNA, a more sensitive direct assay for the presence of HBV particles. As far as improvement in liver disease is concerned the controlled trial of ARA-A7 showed a significant decrease in AST, particularly in those patients who developed antiHBe. Uncontrolled studies with ARA-A and/or human leucocyte interferon have also shown improvement in symptoms, biochemistry, and histology as seroconversion from HBeAg to antiHBe occurred.6 The AST in our three patients eventually fell to below pre-treatment levels. In addition in one there was histological improvement. In the other patient whose liver biopsy remained unchanged, serum viral DNA persisted during the initial period of development of anti-HBe and 13 months after treatment this patient still had HBcAg in the liver. This suggests that viral replication may continue in the liver in the absence of markers in the serumis and that longer periods of histological follow-up may be required.
